KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Cash & Equivalents: 2016-2024

Historic Cash & Equivalents for Moderna (MRNA) over the last 9 years, with Dec 2024 value amounting to $1.9 billion.

  • Moderna's Cash & Equivalents fell 31.14% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year decrease of 31.14%. This contributed to the annual value of $1.9 billion for FY2024, which is 33.71% down from last year.
  • As of FY2024, Moderna's Cash & Equivalents stood at $1.9 billion, which was down 33.71% from $2.9 billion recorded in FY2023.
  • Moderna's 5-year Cash & Equivalents high stood at $6.8 billion for FY2021, and its period low was $1.9 billion during FY2024.
  • For the 3-year period, Moderna's Cash & Equivalents averaged around $2.7 billion, with its median value being $2.9 billion (2023).
  • Per our database at Business Quant, Moderna's Cash & Equivalents soared by 1,011.86% in 2020 and then plummeted by 53.20% in 2022.
  • Yearly analysis of 5 years shows Moderna's Cash & Equivalents stood at $2.6 billion in 2020, then skyrocketed by 160.98% to $6.8 billion in 2021, then crashed by 53.20% to $3.2 billion in 2022, then fell by 9.30% to $2.9 billion in 2023, then slumped by 33.71% to $1.9 billion in 2024.